natgillin/translations-raw huggingface dataset:
After oral administration, metformin absorption is saturable and incomplete. 
Nakon peroralne primjene apsorpcija metformina odvija se do zasićenja i nepotpuna je.
Table 3: Change in HbA1c (%) from baseline with alogliptin 25 mg by active-controlled study (PPS, LOCF) 
Tablica 3: Promjena HbA1c (%) u odnosu na početnu vrijednost za alogliptin 25 mg u ispitivanju kontroliranom aktivnom kontrolom (PPS, LOCF)
Hepatic impairment Vipdomet must not be used in patients with hepatic impairment (see sections 4.3, 4.4 and 5.2). 
Vipdomet se ne smije primjenjivati u bolesnika s oštećenjem jetre (vidjeti dijelove 4.3, 4.4 i 5.2).
The following section outlines the interactions observed with the individual components of Vipdomet (alogliptin/metformin) as reported in their respective Summary of Product Characteristics. 
Sljedeći dio navodi interakcije opažene za pojedinačne komponente Vipdometa (alogliptin/metformin) kako su navedene u Sažetku opisa svojstava lijeka svakog od njih.
These studies evaluated the effects of co-administered alogliptin and metformin on glycaemic control and their safety as initial combination therapy, as dual therapy in patients initially treated with metformin alone, and as add-on therapy to a thiazolidinedione or insulin. 
U ispitivanjima su procijenjeni učinci istodobno primijenjenih alogliptina i metformina na kontrolu glikemije, te njihova sigurnost kao inicijalne kombinirane terapije, kao dvojne terapije u bolesnika koji su inicijalno liječeni samo metforminom, te kao dodatna terapija tiazolidindionu ili inzulinu.
Frequency of adverse reactions Alogliptin Metformin Vipdomet 
Učestalost nuspojava Alogliptin Metformin Vipdomet
Table 2: Change in HbA1c (%) from baseline with alogliptin 25 mg at Week 26 by placebo-controlled study (FAS, LOCF) 
Tablica 2: Promjena HbA1c (%) u odnosu na početnu vrijednost za alogliptin 25 mg u 26. tjednu u placebom kontroliranom ispitivanju (FAS, LOCF)
In vitro studies suggest that alogliptin does not inhibit nor induce CYP 450 isoforms at concentrations achieved with the recommended dose of 25 mg alogliptin (see section 5.2). 
In vitro ispitivanja pokazuju da, u koncentracijama koja se postižu preporučenom dozom od 25 mg, alogliptin ne inhibira niti inducira CYP 450 izoenzime (vidjeti dio 5.2).
Decreased renal function in elderly patients is frequent and asymptomatic. 
Smanjena funkcija bubrega je u starijih osoba česta i asimptomatska.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING INTERMEDIATE CARTON (WITHOUT BLUE BOX) MULTIPACKS ONLY (2X98 TABLETS) 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU UNUTRAŠNJA KUTIJA (BEZ PLAVOG OKVIRA) SAMO VIŠESTRUKA PAKIRANJA (2X98 TABLETA)
The co-administration of alogliptin and metformin has been studied as dual therapy in patients initially treated with metformin alone, and as add-on therapy to a thiazolidinedione or insulin. 
Istodobna primjena alogliptina i metformina ispitana je kao dvojna terapija u bolesnika koji su inicijalno liječeni samo metforminom, te kao dodatak terapiji tiazolidindionu ili inzulinu.
Gastrointestinal disorders gastroenteritis common abdominal pain common very common common diarrhoea common very common common vomiting very common common gastritis common gastroesophageal reflux disease common common loss of appetite very common nausea very common acute pancreatitis not known 
Poremećaji probavnog sustava gastroenteritis često bol u abdomenu često vrlo često često proljev često vrlo često često povraćanje vrlo često često gastritis često gastroezofagealna refluksna bolest često često gubitak apetita vrlo često mučnina vrlo često akutni pankreatitis nepoznato
Your doctor may want to reduce your dose of insulin or a thiazolidinedione when you take it together with Vipdomet in order to avoid too low blood sugar (hypoglycaemia). 
Liječnik će možda htjeti smanjiti dozu inzulina ili tiazolidindiona kada ga uzimate zajedno s Vipdometom kako bi se izbjegao pretjerano nizak šećer u krvi (hipoglikemija) - ako uzimate drugi lijek za šećernu bolest koji sadrži „sulfonilureju“, ne smijete početi uzimati
Infections and infestations upper respiratory tract infections common common nasopharyngitis common common 
Infekcije i infestacije infekcije gornjeg respiratornog trakta često često nazofaringitis često često
Based on mean dialysate concentrations, approximately 7% of the active substance was removed during a 3-hour haemodialysis session.) 
Temeljem srednjih vrijednosti koncentracija dijalizata, u 3-satnoj hemodijalizi ukloni se približno 7% djelatne tvari.)
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON (WITH BLUE BOX) (EXCLUDING MULTIPACKS) 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA (S PLAVIM OKVIROM) (ISKLJUČUJUĆI VIŠESTRUKO PAKIRANJE)
Total exposure to alogliptin was approximately 10% lower and peak exposure was approximately 8% lower in patients with moderate hepatic impairment compared to control subjects. 
U bolesnika s umjerenim oštećenjem jetre je ukupna izloženost alogliptinu bila približno 10% niža, a vršna izloženost alogliptinu oko 8% niža u usporedbi sa zdravim ispitanicima.
The following section outlines the pharmacokinetic properties of the individual components of Vipdomet (alogliptin/metformin) as reported in their respective Summary of Product Characteristics. 
U sljedećem dijelu navedene se farmakokinetička svojstva pojedinačnih sastojaka Vipdometa (alogliptin/metformin) kako su navedene u Sažetku opisa svojstava lijeka svakog od njih.
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/001-026 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/13/843/001-026
- in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control. 
- u kombinaciji s inzulinom (tj. trojna kombinirana terapija), kao dodatak dijeti i tjelovježbi, za poboljšanje kontrole glikemije u bolesnika u kojih nije postignuta odgovarajuća kontrola inzulinom u stabilnoj dozi i metforminom.
For patients inadequately controlled on the maximal tolerated dose of metformin hydrochloride alone, the recommended dose is one tablet of 12.5 mg/850 mg or 12.5 mg/1,000 mg twice daily, corresponding to 25 mg alogliptin plus 1,700 mg or 2,000 mg metformin hydrochloride daily, depending on the dose of metformin hydrochloride already being taken. 
Za bolesnike u kojih adekvatna kontrola nije postignuta maksimalnom podnošljivom dozom samog metforminklorida, preporučena doza je jedna tableta od 12,5 mg/850 mg ili 12,5 mg/1000 mg dvaput na dan, što odgovara dnevnoj dozi od 25 mg alogliptina i 1700 mg ili 2000 mg metforminklorida, ovisno o dozi metforminklorida koju bolesnik već uzima.
Clinically meaningful reductions in HbA1c compared to placebo were also observed with 25 mg alogliptin regardless of whether patients were receiving concomitant metformin or sulphonylurea therapy. 
Klinički značajna sniženja HbA1c u usporedbi s placebom opažena su i za 25 mg alogliptina bez obzira jesu li bolesnici istodobno primali terapiju metforminom ili sulfonilurejom.
How to store Vipdomet 
Kako čuvati Vipdomet
No adverse effects on fertility were observed in animal studies conducted with alogliptin or with metformin (see section 5.3). 
U ispitivanjima na životinjama nisu opažene nuspojave alogliptina ili metformina na plodnost (vidjeti dio 5.3).
Vipdomet must be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.4. 
Primjena Vipdometa se mora prekinuti prije ili u vrijeme pretrage metodom oslikavanja i s njegovom primjenom smije se ponovno započeti tek 48 sati poslije, pod uvjetom da je funkcija bubrega bila ponovno procijenjena i da je potvrđeno da je stabilna, vidjeti dijelove 4.2 i 4.4.
Adults (≥18 years old) with normal renal function (glomerular filtration rate (GFR)≥90 mL/min) The dose should be individualised on the basis of the patient's current treatment regimen. 
Odrasli (≥18 godina starosti) s normalnom funkcijom bubrega (brzina glomerularne filtracije (GFR) ≥90 ml/min)
Vipdomet should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.5. 
Primjenu Vipdometa treba prekinuti prije ili u vrijeme pretrage metodom oslikavanja i s njegovom primjenom smije se ponovno započeti tek 48 sati poslije, pod uvjetom da je funkcija bubrega bila ponovno procijenjena i da je potvrđeno da je stabilna, vidjeti dijelove 4.2 i 4.5.
Liver function test abnormalities very rare hepatic dysfunction including hepatic failure not known 
Poremećaji jetre i žuči hepatitis vrlo rijetko odstupanja u testovima jetrene funkcije vrlo rijetko poremećaj funkcije jetre uključujući zatajenje jetre nepoznato
In rats no treatment-related foetal abnormalities occurred following concomitant administration at exposure margins of approximately 28- to 29-fold for alogliptin and 2- to 2.5-fold for metformin at the maximum recommended human dose of 25 mg/day and 2,000 mg/day, respectively. 
U štakora nisu viđene fetalne abnormalnosti nakon istodobne primjene u marginama izloženosti koje nadmašuju maksimalnu preporučenu dozu od 15 mg/dan i 2000 mg/dan za približno 28 do 29 puta za alogliptin i 2 do 2,5 puta za metformin.
Clinical studies conducted to support the efficacy and safety of Vipdomet involved the co-administration of alogliptin and metformin as separate tablets. 
Klinička ispitivanja provedena za potvrdu djelotvornosti i sigurnosti Vipdometa uključivala su istodobnu primjenu alogliptina i metformina kao zasebnih tableta.
Add-on combination therapy placebo-controlled studies Alogliptin 25 mg once daily with metformin (n=203) 
Ispitivanja dodatka kombiniranoj terapiji kontrolirana placebom Alogliptin 25 mg jedanput na dan s metforminom (n=203)
LOCF = last observation carried forward † Least squares means adjusted for prior antihyperglycaemic therapy status and baseline values * p<0.001 compared to placebo or placebo+combination treatment 
FAS = analiza svih uključenih bolesnika (engl. full analysis set) LOCF = zadnje opažanje preneseno nadalje (engl. last observation carried forward) †Srednja vrijednost temeljena na metodi najmanjih kvadrata prilagođena prema prethodnom antihiperglikemijskom terapijskom statusu i početnim vrijednostima * p<0,001 u usporedbi s placebom ili liječenjem placebom+kombinacijom
In addition, 25 mg alogliptin alone and in combination with 30 mg pioglitazone produced statistically significant (p<0.001) reductions in total triglycerides at Week 16 as measured by postprandial incremental AUC(0-8) change from baseline compared to placebo. 
Dodatno, 25 mg alogliptina, samog ili u kombinaciji s 30 mg pioglitazona, dovelo je u 16. tjednu u odnosu na placebo do statistički značajnih (p<0,001) sniženja ukupnih triglicerida izmjerenih kao postprandijalna inkrementalna promjena AUC(0-8) od početne vrijednosti.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER LABEL (WITH BLUE BOX) MULTIPACKS ONLY (2X98 TABLETS) 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKO OZNAČAVANJE (S PLAVIM OKVIROM) SAMO VIŠESTRUKA PAKIRANJA (2X98 TABLETA)
The safety and efficacy of Vipdomet in children and adolescents <18 years old have not been established. 
Sigurnost i djelotvornost lijeka Vipdomet u djece i adolescenata
Clinically meaningful reductions in HbA1c compared to placebo were also observed with 25 mg alogliptin regardless of whether patients were receiving concomitant metformin therapy. 
Klinički značajna sniženja razina HbA1c u usporedbi s placebom su za 25 mg alogliptina opažena bez obzira na to jesu li bolesnici usporedno primali terapiju metforminom.
Alogliptin 25 mg once daily with a thiazolidinedione + metformin vs a titrating thiazolidinedione + metformin 
Alogliptin 25 mg jedanput na dan s tiazolidindionom+metformin naspram titrirani tiazolidindion+metformin
Therefore, in order to maintain systemic exposures to alogliptin that are similar to those observed in patients with normal renal function, lower doses of alogliptin should be used in patients with moderate or severe renal impairment, or end-stage renal disease requiring dialysis (see above and section 4.2). 
Kako bi se održala sistemska izloženost alogliptinu slična onoj u bolesnika s normalnom funkcijom bubrega, u bolesnika s umjerenim i teškim oštećenjem bubrega, te sa završnim stadijem bolesti bubrega na dijalizi, potrebno je primijeniti nižu dozu alogliptina (vidjeti dio 4.2).
LOCF = last observation carried forward *Non inferiority and superiority statistically demonstrated † Least squares means adjusted for prior antihyperglycaemic therapy status and baseline values 
PPS = bolesnici koji su završili ispitivanje po protokolu (engl. per protocol set) LOCF = zadnje opažanje preneseno nadalje (engl. last observation carried forward) * Dokazana je statistička neinferiornost i superiornost † Srednja vrijednost metodom najmanjih kvadrata prilagođena prethodnom antihiperglikemijskom terapijskom statusu i početnim vrijednostima
Not known: - Liver problems such as nausea or vomiting, stomach pain, unusual or unexplained tiredness, 
Nepoznate učestalosti: - Problemi s jetrom poput mučnine ili povraćanja, boli u trbuhu, neobičnog ili neobjašnjivog umora, gubitka teka, tamne mokraće ili žutila kože ili bjeloočnica.
Although fertility was not affected, a slight, statistical increase in the number of abnormal sperm was observed in males at an exposure far above the human exposure at the recommended dose. 
Iako plodnost nije bila oštećena, u mužjaka je pri izloženosti koja je daleko iznad izloženosti kod ljudi pri preporučenoj dozi opaženo je blago, statističko povećanje broja abnormalnih spermija.
- if you have a severe infection or are seriously dehydrated (have lost a lot of water from your body) - if you recently had a heart attack or have severe circulatory problems including shock - if you have severe breathing difficulties - if you have liver disease - if you drink alcohol excessively (either every day or in large quantities only from time to time) 
Simptomi uključuju bol u trbuhu, ubrzano i duboko disanje, pospanost ili Vam dah ima neobičan voćni miris. - ako imate tešku infekciju ili ste ozbiljno dehidrirani (izgubili ste mnogo vode iz tijela) - ako ste nedavno imali srčani udar ili teže probleme s cirkulacijom uključujući šok - ako imate izrazite teškoće pri disanju.
Alogliptin 25 mg once daily with a thiazolidinedione ± metformin or a sulphonylurea (n=195) 
Alogliptin 25 mg jedanput na dan s tiazolidindionom±metformin ili sulfonilureja (n=195)
Therefore, haemodialysis is of little clinical benefit in removing alogliptin in overdose. 
Stoga je hemodijaliza od male kliničke koristi.
The amount of Vipdomet will vary depending on your condition and the doses you currently take of metformin alone, metformin in combination with pioglitazone, insulin and/or individual tablets of alogliptin and metformin. 
Količina Vipdometa će varirati ovisno o Vašem stanju, te lijekovima i dozama koje trenutačno uzimate, pojedinačno ili u kombinaciji
The results of bioequivalence studies in healthy subjects demonstrated that Vipdomet film-coated tablets are bioequivalent to the corresponding doses of alogliptin and metformin co-administered as separate tablets. 
Rezultati ispitivanja bioekvivalencije u zdravih ispitanika pokazuju da su Vipdomet filmom obložene tablete bioekvivalentne odgovarajućim dozama alogliptina i metformina istodobno primijenjenih kao zasebne tablete.
Table 1: Adverse reactions System organ class Adverse reaction 
Tablica 1: Nuspojave Organski sustav Nuspojava
Hepatic impairment Vipdomet should not be used in patients with hepatic impairment (see section 4.2). 
Vipdomet se ne smije primjenjivati u bolesnika s oštećenjem jetre (vidjeti dio 4.2).
Clinical studies conducted to support the efficacy of Vipdomet involved the co-administration of alogliptin and metformin as separate tablets. 
Klinička ispitivanja provedena za potvrdu djelotvornosti Vipdometa uključivala su istodobnu primjenu alogliptina i metformina kao zasebnih tableta.
A lower dose of insulin may be considered to reduce the risk of hypoglycaemia. 
Kako bi se smanjio rizik od hipoglikemije, potrebno je razmotriti sniženje doze inzulina.
Postmarketing reports of hepatic dysfunction including hepatic failure have been received. 
Nakon stavljanja lijeka u promet primljene su prijave slučajeva disfunkcije jetre uključujući zatajenje jetre.
The significant reductions in HbA1c observed with 25 mg alogliptin plus 30 mg pioglitazone and metformin were consistent over the entire 52-week treatment period compared to 45 mg pioglitazone and metformin (p<0.001 at all time points). 
Značajna sniženja HbA1c opažena s 25 mg alogliptina s 30 mg pioglitazona i metforminom u usporedbi s 45 mg pioglitazona s metforminom bila su dosljedna tijekom čitavog 52-tjednog razdoblja liječenja (p<0,001 u svim vremenskim točkama).
For patients inadequately controlled on dual therapy with a maximal tolerated dose of metformin and pioglitazone, the dose of pioglitazone should be maintained, and Vipdomet administered concomitantly; alogliptin should be dosed at 12.5 mg twice daily (25 mg total daily dose) and metformin hydrochloride at a similar dose (either 850 mg or 1,000 mg twice daily) to that already being taken. 
Za bolesnike u kojih adekvatna kontrola nije postignuta dvojnom terapijom maksimalnom podnošljivom dozom metformina i pioglitazona, dozu pioglitazona treba održavati, i Vipdomet primijeniti istodobno; alogliptin treba dozirati od 12,5 mg dvaput na dan (ukupna dnevna doza 25 mg), a metforminklorid u dozi sličnoj onoj koju bolesnik već uzima (850 mg ili 1000 mg dvaput na dan).
For patients inadequately controlled on dual combination therapy with insulin and the maximal tolerated dose of metformin, the dose of Vipdomet should provide alogliptin dosed at 12.5 mg twice daily (25 mg total daily dose) and a dose of metformin similar to the dose already being taken. 
Za bolesnike u kojih adekvatna kontrola nije postignuta dvojnom terapijom inzulinom i maksimalnom podnošljivom dozom metformina, doza Vipdometa treba osigurati doziranje alogliptina od 12,5 mg dvaput na dan (ukupna dnevna doza 25 mg) i doza metformina slična onoj koju bolesnik već uzima.
INFORMATION IN BRAILLE Vipdomet 12.5 mg/850 mg 
16. PODACI NA BRAILLEOVOM PISMU Vipdomet 12,5 mg/850 mg
No alogliptin-related effects were observed in juvenile rats following repeat-dose administration for 4 and 8 weeks. 
U mladih štakora nakon primjene ponovljenih doza tijekom 4 i 8 tjedana nisu opaženi učinci povezani s alogliptinom.
However, the results of bioequivalence studies have demonstrated that Vipdomet film-coated tablets are bioequivalent to the corresponding doses of alogliptin and metformin co-administered as separate tablets. 
Međutim, rezultati ispitivanja bioekvivalencije dokazali su da su Vipdomet filmom obložene tablete bioekvivalentne odgovarajućim dozama alogliptina i metformina istodobno primijenjenim kao zasebne tablete.
The addition of 25 mg alogliptin once daily to 30 mg pioglitazone in combination with metformin hydrochloride therapy (mean dose = 1,867.9 mg) resulted in improvements from baseline in HbA1c at Week 52 that were both non-inferior and statistically superior to those produced by 45 mg pioglitazone in combination with metformin hydrochloride therapy (mean dose = 1,847.6 mg, Table 3). 
Dodavanje 25 mg alogliptina jedanput na dan terapiji s 30 mg pioglitazona u kombinaciji s metforminkloridom (srednja vrijednost doze = 1867,9 mg) dovelo je u 52. tjednu do poboljšanja HbA1c koje se pokazalo i neinferiornim i statistički superiornim onome postignutom terapijom s 45 mg pioglitazona s metforminom (srednja vrijednost doze = 1847,6 mg, tablica 3).
Alogliptin 25 mg once daily with insulin + metformin (n=126) 
Alogliptin 25 mg jedanput na dan s inzulinom ± metformin (n=126)
In patients with moderate or severe renal impairment, or end-stage renal disease on haemodialysis, an increase in systemic exposure to alogliptin of approximately 2- and 4-fold was observed, respectively. 
U bolesnika s umjerenim ili teškim oštećenjem bubrega, ili završnim stadijem bolesti bubrega na hemodijalizi, opaženo je povećanje sistemske izloženosti alogliptinu od približno 2 i 4 puta. (Bolesnici sa završnim stadijem bolesti bubrega su podvrgnuti hemodijalizi neposredno nakon primjene alogliptina.
Hypoglycaemia 
Hipromeloza
For the different dose regimens Vipdomet is available in strengths of 12.5 mg/850 mg and 12.5 mg/1,000 mg film-coated tablets. 
Za različite režime doziranja Vipdomet je dostupan kao filmom obložene tablete u jačinama od 12,5 mg/850 mg i 12,5 mg/1000 mg.
Both 25 mg alogliptin alone and in combination with 30 mg pioglitazone demonstrated significant decreases in postprandial glucose and postprandial glucagon whilst significantly increasing postprandial active GLP-1 levels at Week 16 compared to placebo (p<0.05). 
U 16. tjednu primjene 25 mg alogliptina, samog i u kombinaciji s 30 mg pioglitazona, postigla su se u odnosu na placebo, značajna smanjenja postprandijalne glukoze i postprandijalnog glukagona uz značajni porast postprandijalnih razina aktivnog GLP-1 (p<0,05).
INFORMATION IN BRAILLE Vipdomet 12.5 mg/1000 mg 
16. PODACI NA BRAILLEOVOM PISMU Vipdomet 12,5 mg/1000 mg
There have been spontaneously reported adverse reactions of acute pancreatitis in the post-marketing setting. 
Nakon stavljanja lijeka u promet bile su spontano prijavljene nuspojave akutnog pankreatitisa.
Hepatobiliary disorders hepatitis very rare 
vrlo rijetko hipoglikemija često često
- Cold symptoms such as sore throat, stuffy or blocked nose, feeling tired, fever, chills, dry cough - Rash - Itchy skin with or without hives - Headache - Indigestion, heartburn - Vomiting and/or diarrhoea - Metallic taste. 
zimice, suhog kašlja - Osip - Svrbež kože s ili bez koprivnjače - Glavobolja - Probavne tegobe, žgaravica
Add-on combination therapy studies Alogliptin 25 mg once daily with metformin vs a sulphonylurea + metformin 
Ispitivanja kao dodatka u kombiniranoj terapiji Alogliptin 25 mg jedanput na dan s metforminom naspram sulfonilureja+metformin
Significantly more patients receiving 12.5 mg alogliptin and 1.000 mg metformin hydrochloride twice daily (59.5%) achieved target HbA1c levels of < 7.0% compared to those receiving either 12.5 mg alogliptin twice daily alone (20.2%, p<0.001) or 1,000 mg metformin hydrochloride twice daily alone (34.3%, p<0.001) at Week 26. 
U 26. tjednu je ciljne razine HbA1c od <7,0% postiglo značajno više bolesnika koji su primali 12,5 mg alogliptina i 1000 mg metforminklorida (59,5%) nego oni koji su primali ili samo alogliptin 12,5 mg dvaput na dan (20,2%, p<0,01) ili samo metforminklorid dvaput na dan (34,3%, p<0,001).
Obtain liver function tests promptly in patients with symptoms suggestive of liver injury. 
U bolesnika sa simptomima koji ukazuju na oštećenje jetre treba odmah napraviti jetrene funkcijske testove.
Significantly more patients receiving 25 mg alogliptin plus 30 mg pioglitazone and metformin (33.2%) achieved target HbA1c levels of ≤7.0% compared to those receiving 45 mg pioglitazone and metformin (21.3%) at Week 52 (p<0.001). 
HbA1c od ≤ 7,0% postiglo značajno više bolesnika koji su primali 25 mg alogliptina s 30 mg pioglitazona i metforminom (33,2%) nego onih koji su primali 45 mg pioglitazona s metforminom (21,3%) (p<0,001).
- in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation. 
- smanjenjem stvaranja glukoze u jetri inhibicijom glukoneogeneze i glikogenolize - u mišićima, skromnim povećanjem osjetljivosti na inzulin, poboljšavajući perifernu pohranu i iskorištavanje glukoze - odgađanjem apsorpcije glukoze u crijevu.